Innovative biotherapeutics

As part of the expected launch of a new biotherapeutic solution to fight psoriasis, Alcimed supported a leading client in the pharmaceutical industry to optimize its engagement plan for its prescribers.

In this context, our team explored the challenges of the prescribers’ practice and patient management throughout their journey and assessed the level of receptivity of prescribers to this future solution.

Alcimed’s recommendations made it possible to adjust the messages and target key prescribers for a successful launch.

Alcimed supported one of its clients to ensure the transition between two biotherapeutics: one already on the market in a leading position, the other in the process of being launched.

Through a targeted bibliographic analysis, interactions with the various stakeholders, and the organization of a workshop, our team analyzed the respective receptivity of the two biotherapeutics among prescribers and the strengths and weaknesses of the client’s products, identified the specific expectations of prescribers, and assessed the impact of newcomers on our client’s two biotherapeutics.

Inspired also by other examples of successful transition outside the market under consideration, we were able to define the major key steps of the transition to be carried out and order them over time so as to maintain our client’s leadership position.

Alcimed supported one of its leading clients in immunotherapy to understand how to position itself in personalized medicine and what arguments to put forward to differentiate itself from the competition.

Through bibliographic research and interviews with experts, our team investigated to understand the expectations of the different stakeholders of this specific care chain in terms of personalized medicine, and how our client could legitimize its place in this field from a scientific and medical point of view.

This research made it possible to build a precise sales pitch for medical sales representatives and MSLs and to prepare the materials used during a webinar and a congress with the medical professionals.

Alcimed supported one of its clients, a global pharmaceutical leader, to characterize the advanced biotherapeutics market by evaluating the top 30 molecules for human use in this market, in order to identify potential partners to develop and strengthen its production platform.

Subsequently, our team compared the cost-benefit balance of the identified innovative technologies against conventional technologies and tested the receptivity of potential partners to enable our client to expand its production activities.

Alcimed supported one of the world’s leading in vitro diagnostic companies in the evaluation of a diagnostic technology to monitor the efficacy of new biotherapies and to detect unwanted immunosuppression.

Through targeted literature searches, interactions with key experts involved in the development of new biotherapies and the organisation of a workshop, our team assessed the interest of pharmaceutical companies in the technology being developed and identified the specific expectations of the market, particularly in terms of applications and categories of biotherapies to be prioritised.

Among other things, our work helped our client to prepare a response to a European call for projects.

Alcimed supported a cell therapy player in a project aimed at identifying and understanding the possible routes of access for its new therapy in Parkinson’s patients.

By conducting investigations in 6 countries on 2 different continents, our team mapped the stages in the Parkinson’s patient pathway in order to identify the best route to the patient and tested the receptivity to this new therapy in each country of interest. Based on the available literature and feedback from opinion leaders on the subject, we constructed hypotheses to estimate the potential market for this new therapy by country.

The work carried out by our team provided our client with the key elements needed to rationalise its development strategy and its future clinical trials.

We supported a European pharmaceutical company in the pre-launch phase of the first gene therapy for a given pathology. The question was how to best prepare the acceptance by the healthcare authorities of this innovative therapy, delivered punctually and a priori with a high cost compared to the reference drugs.

We were able to assess the perception of public institutions and prescribers of the value provided by this gene therapy drug, thanks to discussions and a benchmark of already approved gene therapies, then tested the potential of different funding models for this biotherapy (ex: “Pay-for-Performance”, subscription model, etc.).

An innovative access model emerged, supported by a pan-European action plan to ensure the successful marketing of our client’s gene therapy.

We supported a pharma player in achieving their market access strategy through the understanding of payers’ expectations, requirements and receptivity to gene therapies targeting rare diseases in the USA and in 5 European countries.

At first, our team deciphered the Pricing & Reimbursement (P&R) organizations, processes and country-dependent specificities for expensive gene therapies in the next 5-10 years. In a second phase, we analyzed payers’ expectations/requirements on types of evidence for a gene therapy and their receptivity to innovative funding models. Finally, our team completed the payers’ landscape with a case study from an already-marketed gene therapy.

In the end, we gave our client recommendations on how to achieve market access of a gene therapy in the US and EU5 and on how payers’ expectations and country-dependent specificities should be taken into consideration in the design of clinical studies.